*Note: For the investigational use of Adipose-Derived Stem Cells (ADSC’s) for clinical research and deployment.
Peyronies Disease “PD” has been described by experts as a physically and psychologically devastating problem manifested by a fibrous inelastic scar of the fibrous chambers of the penis known as the tunica albuginea. The scarring (known as “Peyronies plaques”) can cause pain, bending, narrowing, hinging and shortening of the penis in the erect state. Recent demographic studies have shown that up to 9% of men have this problem and it seems to be even more prevalent after radical prostatectomy surgery. More than half of the cases worsen over time and only 13% resolve spontaneously. Peyronies is also closely associated with erectile dysfunction.
There is no known non-surgical cure for PD and surgery can often result in more scarring, shortening or loss of sensation and adequate erectile function. Cases that involve calcification seem to do the worst with non-surgical treatment. Non-surgical therapies include Vitamin E, Potaba, colchicine, tamoxifen, carnitine, and Omega-3 fatty acids. Unfortunately, formal studies have shown no benefit of any of these over placebo.
Stem Cells And Peyronies Disease
Stem cell therapy has proven effective in the treatment of Peyronie’s disease. Injections of fat-derived stem cells into the penis are used to straighten the erection and improve the elasticity of connective tissue.
There is evidence that stem cells will actively seek out and attempt to repair a Dupuytren’s contracture which is nearly identical to PD but occurs in the hand. Stem cells may be highly effective in inflammatory scarring conditions occurring in other parts of the body. We have developed a protocol for intralesional injection of the autologous adipose-derived stromal vascular fraction (rich in mesenchymal stem cells and growth factors) directly into Peyronies plaques as a non-surgical option for patients who have not responded to other conservative measures but wish to avoid surgery. Some patients will also be eligible to receive low-intensity shock wave therapy in conjunction with SVF deployment in an effort to activate the stem cells to induce revascularization and healing.